Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem.

Kure EH, Hamfjord J, Stangeland AM, Tveit KM, Ikdahl T.

Expert Rev Mol Diagn. 2012 May;12(4):327-8. doi: 10.1586/erm.12.29. No abstract available.

PMID:
22616697
2.

KRAS mutational test for metastatic colorectal cancer patients: not just a technical problem.

Molinari F, Frattini M.

Expert Rev Mol Diagn. 2012 Mar;12(2):123-6. doi: 10.1586/erm.11.94.

PMID:
22369372
3.

Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients.

Zavodna K, Konecny M, Krivulcik T, Spanik S, Behulova R, Vizvaryova M, Weismanova E, Galbavy S, Kausitz J.

Neoplasma. 2009;56(3):275-8.

PMID:
19309232
4.

A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer.

Adelstein BA, Dobbins TA, Harris CA, Marschner IC, Ward RL.

Eur J Cancer. 2011 Jun;47(9):1343-54. doi: 10.1016/j.ejca.2011.03.031. Epub 2011 May 5. Review.

PMID:
21550229
5.

Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma.

Krol LC, 't Hart NA, Methorst N, Knol AJ, Prinsen C, Boers JE.

Eur J Cancer. 2012 May;48(7):1108-15. doi: 10.1016/j.ejca.2012.02.054. Epub 2012 Mar 23.

PMID:
22446020
6.

BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?

Velho S, Moutinho C, Cirnes L, Albuquerque C, Hamelin R, Schmitt F, Carneiro F, Oliveira C, Seruca R.

BMC Cancer. 2008 Sep 9;8:255. doi: 10.1186/1471-2407-8-255.

7.

New strategies for treatment of KRAS mutant metastatic colorectal cancer.

Prenen H, Tejpar S, Van Cutsem E.

Clin Cancer Res. 2010 Jun 1;16(11):2921-6. doi: 10.1158/1078-0432.CCR-09-2029. Epub 2010 May 11. Review.

Supplemental Content

Support Center